New Frontiers for
Neuromuscular Blockade Use and Reversal: Addressing Challenges for
Improved Clinical and Economic Outcomes
A continuing medical
education activity sponsored by NAMCP and AAMCN
New Frontiers for Neuromuscular Blockade Use and Reversal:
Addressing Challenges for Improved Clinical and Economic Outcomes is
a two-part webinar series focusing on the latest developments in the
use and reversal of neuromuscular blockade
These are archives of live webinars held between August 10 and
August 12, 2020.
If you participated in any of the live webinars, you are not
eligible to claim credit from the archive of that webinar.
By clicking on each of the titles, you will be able to participate
in each part.
It is not required that you participate in all three or in order.
These activities are valid from August 15, 2020 to August 15, 2022
series is supported by an educational grant from Merck Sharp & Dohme
This activity is intended for healthcare professionals practicing in managed
Instructions for CME/NCPD: Complete the pre-test,
listen to the audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your internet
browser without completing the post test, you will have ONE more opportunity to
complete. A score of 70% must be achieved on the post test to receive continuing
education credits. If you do not pass the post test after two attempts, you will
not be eligible to try again. Once you complete the evaluation form and score
70% or higher on your post test, you will automatically be given your
Neuromuscular blocking agents (NMBAs) are used in many surgical procedures and
have enabled new surgical advances. The expanded landscape of NMB reversal drugs
allows for fast and complete neuromuscular blockade (NMB) reversal and the
reduction of postoperative complications from residual block. In the United
States, neostigmine/glycopyrrolate and sugammadex are the primary agents for
pharmacologic antagonism of NMBAs. While neostigmine and an anticholinergic have
been available for decades, sugammadex has only recently become available. This
webinar will take a close look at these options and what managed care needs to
know about NMB and reversal in a variety of surgeries and clinical settings in
which the use of NMB reversal agents played a significant role in the patients'